Setanaxib, a first-in-class selective NADPH oxidase 1/4 inhibitor for primary biliary cholangitis: A randomized, placebo-controlled, phase 2 trial.
- DOI
- 10.1111/liv.15596
- Published
- 2023 Jul
- Container
- Liver international : official journal of the International Association for the Study of the Liver
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1111/liv.15596,
title = {Setanaxib, a first-in-class selective NADPH oxidase 1/4 inhibitor for primary biliary cholangitis: A randomized, placebo-controlled, phase 2 trial.},
author = {Invernizzi P and Carbone M and Jones D and Levy C and Little N and Wiesel P and Nevens F and study investigators},
year = {2023},
journal = {Liver international : official journal of the International Association for the Study of the Liver},
doi = {10.1111/liv.15596},
url = {https://doi.org/10.1111/liv.15596}
}RIS
TY - JOUR TI - Setanaxib, a first-in-class selective NADPH oxidase 1/4 inhibitor for primary biliary cholangitis: A randomized, placebo-controlled, phase 2 trial. AU - Invernizzi P AU - Carbone M AU - Jones D AU - Levy C AU - Little N AU - Wiesel P AU - Nevens F AU - study investigators PY - 2023 JO - Liver international : official journal of the International Association for the Study of the Liver DO - 10.1111/liv.15596 UR - https://doi.org/10.1111/liv.15596 ER -
APA
P, I., M, C., D, J., C, L., N, L., P, W., F, N., & investigators, S. (2023). Setanaxib, a first-in-class selective NADPH oxidase 1/4 inhibitor for primary biliary cholangitis: A randomized, placebo-controlled, phase 2 trial.. Liver international : official journal of the International Association for the Study of the Liver. https://doi.org/10.1111/liv.15596
Source records
- pubmed · retrieved 2026-09-27T08:42:47.881Z